The global diabetic nephropathy market revenue was around US$ 2.0 billion in 2022 and is estimated to reach US$ 3.3 billion by 2031, growing at a compound annual growth rate (CAGR) of 6% during the ...

The diabetic nephropathy market is driven by the growing burden of diabetes and the increasing demand for effective treatments for kidney disease. Advances in therapeutics, including new drug classes ...

Table 1. Diabetic Nephropathy Stages: Cutoff Values of Urine Albumin for Diagnosis and Main Clinical Characteristics Stages Albuminuria cutoff values (ref. 14) Clinical characteristics (ref. no.) ...

We are currently confronted with an epidemic of renal failure caused by diabetic nephropathy. It has become apparent that blood pressure is a major determinant of the risk of developing diabetic ...

A new study published in the journal of Frontiers in Endocrinology showed that patients with type 2 diabetes mellitus who ...

Post hoc results support the initiation of SGLT2 inhibitors in patients with diabetic nephropathy regardless of iron deficiency. Canagliflozin treatment may improve iron markers and hemoglobin levels ...

China: A recent retrospective cohort study published in Diabetes, Metabolic Syndrome and Obesity has revealed a significant U ...

2025年6月7日，第62届欧洲肾脏协会年会（ERA）在奥地利维也纳圆满落幕。作为全球肾脏病学领域顶尖的学术盛会，本次会议汇聚了众多国际知名专家，并展示了多项前沿突破与创新实践成果。我国肾脏病学者共有90余篇研究摘要入选本届大会，研究内容涵盖肾脏病学 ...

Diabetic nephropathy is the name given to kidney damage caused by diabetes. It develops slowly, over many years, and is also referred to as kidney disease or chronic kidney disease. Diabetic kidney ...

Morphic Therapeutic Inc. has identified compounds acting as integrin αvβ1 antagonists reported to be useful for the treatment of cancer, chronic kidney disease, diabetic nephropathy, pulmonary ...